US$ 650 million is needed annually to diagnose and treat over 1.5 million patients with drug-resistant TB by 2015. This is in line with TB universal access aims for 2010 and the 2015 Stop TB Partnership targets.
The figure was presented to delegates at the opening session of the 14th Conference on Retroviruses and Opportunistic Infections by Dr Paul Nunn of the WHO Stop TB Department. It includes US$ 42 million for global and regional coordination and planning, and technical support. WHO also estimates that more than US$ 600 million is needed for countries to create or expand programmes that manage drug-resistant TB. Just under US$ 200 million of this amount is already budgeted for by countries using domestic or international funds, leaving a gap of about US$ 400 million.
The detailed plan is now circulating among WHO's major partners for consultation.
-
Full text of Dr Paul Nunn's speech at the 14th Conference on Retroviruses and Opportunistic Infections on "Transmission of Extreme Drug Resistant TB in South Africa and Implications for Infection Control in Health Care Settings", 25 February 2007
pdf, 318kb - Webcast
-
XDR-TB news update (March)
pdf, 147kb